Nxera Pharma Secures Lucerastat Rights for Japan and Asia-Pacific Markets
Nxera Pharma secured exclusive rights to the Phase 3 oral therapy candidate lucerastat for Japan and selected Asia-Pacific markets.
Related stories
Alphabet Shares Plunge 13% as AI Concerns Rattle Markets
Google shares fell 13%, while European stocks and bonds held steady, according to the headline.
M impact | EQUITY | Oct 29, 2026, 02:24 PM UTC
Nasdaq Falls More Than 1% as Alphabet Results Rekindle AI Spending Concerns
The tech-heavy Nasdaq fell more than 1% on Thursday as Alphabet's results revived worries about rising AI costs. Investors also assessed fresh inflation data after the Federal Rese
M impact | EQUITY | Oct 29, 2026, 02:23 PM UTC
Hilton Grand Vacations Reports Quarterly Results
Hilton Grand Vacations reported results for the quarter ended September 30. The supplied text contains no financial figures.
M impact | EQUITY | Oct 29, 2026, 02:23 PM UTC
Deepak Nitrite Q2 Profit More Than Triples to ₹398 Crore
Net profit rose to ₹398 crore from ₹118.7 crore a year earlier. Revenue increased 61.7% year on year to ₹3,076 crore from ₹1,901.9 crore.
M impact | EQUITY | Oct 29, 2026, 02:22 PM UTC
Garware Technical Fibres Q2 Net Profit Rises 83.4% to ₹58.6 Crore
Net profit for the second quarter of FY27 rose 83.4% year on year to ₹58.6 crore, while revenue increased 33% to ₹462.6 crore.
M impact | EQUITY | Oct 29, 2026, 02:22 PM UTC
Suryoday SFB Q2 Net Profit More Than Doubles to ₹77 Crore
Suryoday Small Finance Bank reported net profit of ₹77 crore in the second quarter, compared with ₹30 crore a year earlier. Net interest income rose 43% year on year.
M impact | EQUITY | Oct 29, 2026, 02:22 PM UTC